| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
FHV-1(IC50=5.2 μM)
Ganciclovir hydrate targets viral DNA polymerase. It is a deoxyguanosine analogue that is phosphorylated to ganciclovir triphosphate, which inhibits the replication of viral DNA by viral DNA polymerase. It is particularly effective against CMV. |
|---|---|
| ln Vitro |
Acyclic deoxyguanosine analog ganciclovir (BW 759) has better anti-CMV activity than acyclovir while sharing structural similarities with the latter. Compared to 72 μM for acyclovir, the median Ganciclovir concentration needed to inhibit viral replication by 50% is 2.15 μM[4].
Ganciclovir-5'-triphosphate (ganciclovir-TP) inhibits the replication of viral DNA, which is the main mechanism by which ganciclovir works against CMV. A particular and strong inhibition of the viral DNA polymerase is part of this inhibition. Three main cellular enzymes convert ganciclovir to its triphosphate form: phosphoglycerate kinase, guanylate kinase, and a deoxyguanosine kinase that is activated by CMV-infected cells[5]. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses and adenovirus serotypes. It is a nucleoside analogue that is structurally similar to acyclovir but has superior activity against CMV. Its primary mechanism of action is inhibition of viral DNA replication by ganciclovir triphosphate. |
| ln Vivo |
Ganciclovir (BW 759) (50 mg/kg; intraperitoneal; twice daily for five injections) can diffuse into the brain and the perilymphatic space of the inner ear and dramatically reduce white blood cells, red blood cells, and platelets in newborn mice[3].
Ganciclovir (1–80 mg/kg; i.h.; daily for 5 days) postpones mortality and wasting syndrome brought on by the murine cytomegalovirus (MCMV)[6]. Ganciclovir hydrate is used to treat or prevent cytomegalovirus infections. It is an orally active antiviral agent. It is also active against members of the herpes group and some other DNA viruses in vitro. It is a therapeutic agent for CMV infections. |
| Enzyme Assay |
Ganciclovir hydrate is evaluated in cell-free assays for its ability to inhibit viral DNA polymerase. The compound is phosphorylated to its active triphosphate form, and the inhibition of viral DNA polymerase activity is measured. IC50 values are determined.
|
| Cell Assay |
Ganciclovir hydrate is assessed in cell-based antiviral assays using virus-infected cells. Cells are infected with CMV or HSV and treated with Ganciclovir hydrate. Viral replication is measured by quantifying viral DNA or protein levels, or by assessing cytopathic effect reduction.
|
| Animal Protocol |
Animal Model: Albino rats and non-inbred Oncins France 1 (OF1) mice are not immune to MCMV[3]
Dosage: 50 mg/kg Administration: Intraperitoneal injection, twice daily for three days (adult rats) or five injections (mice) (Pharmacokinetic Study) Result: Ganciclovir's intracochlear diffusion in adult rats has been demonstrated to reach blood-level concentrations. Transplacental diffusion was seen in gestating mice, exhibiting a 0.5 fetal-to-maternal blood ratio. Ganciclovir's plasma concentration profile in neonatal mice peaked at two hours and then gradually decreased. The concentration in adult mice peaked one hour after injection, but by two hours later, it was no longer detectable. reduced platelets, red blood cells, and white blood cells in neonatal mice significantly. Ganciclovir hydrate is administered orally or intravenously in animal models and in clinical settings to treat CMV infections. It is used to prevent and treat CMV infections in immunocompromised patients. However, specific animal study protocols are not extensively documented. |
| ADME/Pharmacokinetics |
Ganciclovir hydrate has a molecular weight of 265.23 and a molecular formula of C9H13N5O4·H2O. It has a CAS number of 1359968-33-4. The compound is soluble in water. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Ganciclovir hydrate beyond its known use as an antiviral agent. The compound is a therapeutic agent and is not for research purposes only. It can have significant side effects, including myelosuppression.
|
| References | |
| Additional Infomation |
Ganciclovir hydrate is a nucleoside analogue and an orally active antiviral agent. It has a CAS number of 1359968-33-4. It is used to treat or prevent cytomegalovirus infections. It is a therapeutic agent.
|
| Molecular Formula |
C9H15N5O5
|
|---|---|
| Molecular Weight |
273.245901346207
|
| Exact Mass |
273.107
|
| Elemental Analysis |
C, 39.56; H, 5.53; N, 25.63; O, 29.28
|
| CAS # |
1359968-33-4
|
| Related CAS # |
Ganciclovir;82410-32-0;Ganciclovir sodium;107910-75-8
|
| PubChem CID |
76449958
|
| Appearance |
White to off-white solid powder.
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
19
|
| Complexity |
429
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KLXHZXWXXKSKRU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H13N5O4.H2O/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);1H2
|
| Chemical Name |
2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-3H-purin-6(9H)-one hydrate
|
| Synonyms |
BW-759; RS-21592; BW 759; RS 21592; BW759; BIOLF-62; RS21592; Ganciclovir; Ganciclovir Sodium; trade names: Cytovene; Cymevene; Vitrasert.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6597 mL | 18.2983 mL | 36.5965 mL | |
| 5 mM | 0.7319 mL | 3.6597 mL | 7.3193 mL | |
| 10 mM | 0.3660 mL | 1.8298 mL | 3.6597 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
